Latest / Earn Your Leisure / Top Biotech Investment Picks & How AI is Transforming Healthcare

Transcript

Top Biotech Investment Picks & How AI is Transforming Healthcare · Earn Your Leisure

• 0:00
  Speaker 1: Biotech, biotech checking. We haven't talked about biotech in a while,
• 0:05
  Speaker 1: but you know in in in the Age of ai
• 0:09
  Speaker 1: H and I thought it was interesting that in video
• 0:11
  Speaker 1: when we spoke, when we spoke with some of the
• 0:13
  Speaker 1: people in the video, that we had a couple of
• 0:15
  Speaker 1: panels that some of the employees spoke on and probably
• 0:20
  Speaker 1: the number one thing that was talked about was medical Okay, yep,
• 0:24
  Speaker 1: probably for like over twenty minutes, they had a detailed
• 0:27
  Speaker 1: conversation about medical advancements and how their technology is going
• 0:34
  Speaker 1: to change medicine as far as you know, hospital experiences
• 0:39
  Speaker 1: and inpatient visits, doctors, different things that nature. That gave
• 0:43
  Speaker 1: us a whole a whole blueprint of how you know,
• 0:46
  Speaker 1: the medical industry will change because of artificial intelligence and
• 0:50
  Speaker 1: their technology specifically and the things that they were working
• 0:53
  Speaker 1: on when it comes to the medical field. So that's
• 0:57
  Speaker 1: one aspect of it. But you know, the biotech is
• 1:00
  Speaker 1: a big industry, So what's the biotech check in?
• 1:05
  Speaker 2: And I want to say, off of that point, for
• 1:07
  Speaker 2: those who think that in video trade is done, I
• 1:13
  Speaker 2: just want to be very clear, not just because I
• 1:15
  Speaker 2: picked it and YadA YadA. In video is like the
• 1:19
  Speaker 2: Blackrock of AI. I will say that we can talk
• 1:21
  Speaker 2: about it more in detail, but given how much they're
• 1:24
  Speaker 2: investing into the space and how they have their partnership structure,
• 1:27
  Speaker 2: I think it's fascinating. But on the biotech side, these
• 1:31
  Speaker 2: are three that you can write down, so you have
• 1:33
  Speaker 2: the ETF side. IBB great return, so if you don't
• 1:37
  Speaker 2: want to have to guess which ones to invest in,
• 1:39
  Speaker 2: you can just invest in the basket of them. Number
• 1:42
  Speaker 2: two Gilead, Gilead Scientists is an incredible company, has been
• 1:47
  Speaker 2: through and through. And number three is one that's been
• 1:50
  Speaker 2: in stock club forever and one that I don't talk
• 1:52
  Speaker 2: about publicly, and it's outpacing a lot of companies year
• 1:56
  Speaker 2: over year, and that's Amgen. I think Amgen's probably one
• 2:00
  Speaker 2: one of the greatest companies on the planet and one
• 2:01
  Speaker 2: of the best run ones in the biotech space. And
• 2:05
  Speaker 2: also Nvidia and Lily has the partnership. So it's a
• 2:09
  Speaker 2: lot of exciting things with AI. This happened as a result.
• 2:13
  Speaker 2: But if I had to put my money all on three,
• 2:14
  Speaker 2: it would be IBB, Amgen, which has been a top
• 2:17
  Speaker 2: picking stock stock club forever, and Gilead Sciences. That will
• 2:20
  Speaker 2: round up my top three.
• 2:22
  Speaker 3: There's a solid three. That's a solid three. Obviously we'll go,
• 2:25
  Speaker 3: We'll go, Lily, And I think, like you said, just
• 2:28
  Speaker 3: sometimes things don't need to be explicitly explained to you.
• 2:32
  Speaker 3: It's like the implicit intrinsic value of what's being said.
• 2:35
  Speaker 3: And like you said, when you sit there and you
• 2:37
  Speaker 3: listen to engineers in the field of healthcare when it
• 2:40
  Speaker 3: relates to AI and how the timeframes that it takes
• 2:44
  Speaker 3: to do things has just been shortened by technology.
• 2:47
  Speaker 2: Right.
• 2:47
  Speaker 3: They talked about doing genail and how it used to
• 2:50
  Speaker 3: take eight years and now they've got it down to
• 2:52
  Speaker 3: four hours, and like, what's that going to be in
• 2:54
  Speaker 3: the next three years? Is it take two? I mean,
• 2:56
  Speaker 3: just insanity, So I would take a different three. I
• 3:00
  Speaker 3: love your three. I just want to add and give
• 3:02
  Speaker 3: people as much value as possible. So I have literally
• 3:05
  Speaker 3: obviously as one, I have biogen. And this is interesting
• 3:10
  Speaker 3: because when when you hear biogen, the ticker is b
• 3:13
  Speaker 3: I I B. This is one that focuses on specific things, right,
• 3:18
  Speaker 3: So when I'm talking about in the world of biotech,
• 3:23
  Speaker 3: do they dominate in a specific area, right, Like when
• 3:26
  Speaker 3: we talk about GLPS, who's the dominant player in that,
• 3:29
  Speaker 3: like Biogen is a dominant in the neuro degenerative drugs. Right,
• 3:34
  Speaker 3: So we're talking about things that help treat Alzheimer's, things
• 3:37
  Speaker 3: that help to treat Parkinson's disease. They are leaders in that,
• 3:41
  Speaker 3: So Biogen would be one because I think the science
• 3:44
  Speaker 3: that is going to prevail in the future will go
• 3:46
  Speaker 3: into that space. How do we make things that were
• 3:49
  Speaker 3: once not curable now curable?
• 3:51
  Speaker 1: Right?
• 3:52
  Speaker 3: How do we shorten the time for that? And then
• 3:54
  Speaker 3: I got a sleeper here, man, I watched the chart
• 3:57
  Speaker 3: and obviously you know the topic list here, but Vertex's
• 3:59
  Speaker 3: pharmaceuticals ticker vr X another one that if you look
• 4:06
  Speaker 3: specifically at what they do and what they dominate at, Yeah,
• 4:10
  Speaker 3: is it an over leveraging the sense because they're dominant
• 4:13
  Speaker 3: at one thing? Well, we just talked about the riches
• 4:17
  Speaker 3: in those niches, right, and so they specifically focus on
• 4:20
  Speaker 3: being dominant in the treatment and care of CISTE fibrosis.
• 4:24
  Speaker 3: That is their thing, right, They're not doing glps. That
• 4:27
  Speaker 3: is their thing. That's been their thing, and they've dominated
• 4:29
  Speaker 3: at that. And so when you and this is a tricky,
• 4:33
  Speaker 3: tricky sector when we're talking about biotech, we talked about
• 4:37
  Speaker 3: this years ago. Yeah, it can come and it can go,
• 4:40
  Speaker 3: and it's tough to predict because science takes time. Cures
• 4:44
  Speaker 3: take time, treatments take time, testing, trials, all those things
• 4:48
  Speaker 3: factor in, pricing, factors in, and so it's a tough
• 4:50
  Speaker 3: sector to deal with. But I like the ones that
• 4:53
  Speaker 3: dominate in specific things, and so Lily, obviously, Biogen and
• 4:56
  Speaker 3: Vertex all have different dominant features, different things that they do,
• 5:00
  Speaker 3: but they're leading in those spaces.
• 5:03
  Speaker 2: Yeah, they remind me a little bit of Nvidio when
• 5:06
  Speaker 2: a m D was in the leite. They were so
• 5:07
  Speaker 2: good at one thing, eventually you would see them branch
• 5:10
  Speaker 2: out to others. Definitely a sleeper, and in this case,
• 5:14
  Speaker 2: the cream rises to the top. Like they've had some
• 5:17
  Speaker 2: tumultuous years. Twenty two is kind of tough. But with
• 5:20
  Speaker 2: this list Vertex, Amgen, Biogen, gilly ad like the cream
• 5:26
  Speaker 2: rose to the top. The players that were kind of
• 5:29
  Speaker 2: on the fringes have died out, So I don't think
• 5:31
  Speaker 2: you can go wrong with this list.
• 5:34
  Speaker 3: Yes, shout outs to the chat they got some of
• 5:36
  Speaker 3: these in their portfolios already already, Yep, after them.
• 5:41
  Speaker 1: Okay, but what do these be? What these be advisable investments.
• 5:46
  Speaker 2: No, absolutely, Amgen is one of the top performers in
• 5:49
  Speaker 2: stock Club. Stock Club. If you're in the chat for
• 5:52
  Speaker 2: fire and chat, if am Gen has been performing well,
• 5:54
  Speaker 2: for sure, Amgen, for sure, IBB great exposure, Gilliat would
• 5:58
  Speaker 2: be third. But if you just do ib am Gin
• 6:00
  Speaker 2: and Lily, Holy Trinity, Holy Trinity, you think speed felt good?
• 6:05
  Speaker 2: What I show speed portfolio for sure, IBB, am Gen
• 6:11
  Speaker 2: and Lily together, great combination, great combination.
• 6:16
  Speaker 1: Shout out to in Video once again. Yeah, they definitely
• 6:20
  Speaker 1: talked a lot about healthcare, and I think that was
• 6:23
  Speaker 1: the key takeaway at least for me, was you know,
• 6:25
  Speaker 1: they really hammered it that they're not they don't make anything.
• 6:28
  Speaker 1: They said that Haraian different times. It's like, we don't,
• 6:30
  Speaker 1: we don't make anything. You know, they're a software company.
• 6:33
  Speaker 1: They talked about that also, like most people think their
• 6:35
  Speaker 1: hardware company is actually a software company. And so when
• 6:39
  Speaker 1: you think of in video, most people thinking video as
• 6:41
  Speaker 1: a chip company. But I look at in video as
• 6:45
  Speaker 1: a medical company, as a gaming company, as a sports company,
• 6:51
  Speaker 1: because it's every it's everything everybody anything you put their
• 6:56
  Speaker 1: technology in, that's what it is. So medical industry. They
• 7:01
  Speaker 1: was very very enthusiastic about that, spoke a lot about that,
• 7:05
  Speaker 1: So that should give you some insight if you're interested
• 7:08
  Speaker 1: as far as where they're thinking about going. They also
• 7:11
  Speaker 1: spoke about robotics. They also spoke about autonomous driving vehicles,
• 7:16
  Speaker 1: and they showed us their garage, the autonomous driving garage.
• 7:19
  Speaker 1: So that's a few things that you guys might be
• 7:22
  Speaker 1: interested in if they if you're interested in as far
• 7:24
  Speaker 1: as some insight into the company, and shout out to
• 7:27
  Speaker 1: Peter and Nas. You know, when we came back, when
• 7:29
  Speaker 1: we came back from in Video, we had dinner with
• 7:32
  Speaker 1: Nas and we was talking about in video.
• 7:34
  Speaker 3: We gotta let that breathe like that brief in two seconds.
• 7:39
  Speaker 2: He's been breathing over these things. So I was on
• 7:41
  Speaker 2: the phone with a million the other.
• 7:42
  Speaker 3: Day like, oh yeah that Nas, Yeah, that got you
• 7:48
  Speaker 3: that That never that always is going to be like
• 7:52
  Speaker 3: pretty surreal, Like you walk into the restaurant and it's no,
• 7:55
  Speaker 3: what's up, Troy, It's good, let's go, Like it's just
• 7:58
  Speaker 3: huh what man.
• 8:00
  Speaker 2: He's one of the greatest investors, like hands out of
• 8:02
  Speaker 2: this era. Like if you put his returns up against
• 8:05
  Speaker 2: any VC firm. It's not talked about in that light,
• 8:09
  Speaker 2: but he's outperformed majority of them.
• 8:12
  Speaker 1: Well, the thing and the reason why I said that
• 8:13
  Speaker 1: is the reason why could you know obviously he's on
• 8:15
  Speaker 1: a run right now. He's involved in the casino. You know,
• 8:19
  Speaker 1: everybody's seeing his investment portfolio. Massive Pill arguably had the
• 8:23
  Speaker 1: best year in rap as far as all the albums
• 8:25
  Speaker 1: that they put out. But you know, with him, he
• 8:28
  Speaker 1: was just like, yo, damn, I gotta learn about He's like, yo,
• 8:32
  Speaker 1: y'all gotta next time. Y'all got to take me like
• 8:34
  Speaker 1: d like asking us questions like Yo, what they what
• 8:37
  Speaker 1: was they talking about? What did they have?
• 8:38
  Speaker 3: Like?
• 8:39
  Speaker 1: So I say that to say he's obviously extremely successful person. Right,
• 8:42
  Speaker 1: That's that goes what I'm saying. But he spent more
• 8:47
  Speaker 1: time asking questions than talking. So somebody like somebody like
• 8:53
  Speaker 1: that who's a legend icon, can you know, spend time
• 9:00
  Speaker 1: asking questions? You gotta you gotta be able to you know,
• 9:06
  Speaker 1: receive the information. And that's why this show is so
• 9:08
  Speaker 1: And his partner Peter, he was like he actually he
• 9:11
  Speaker 1: actually watches market mondays and implements on the information. So
• 9:16
  Speaker 1: you know, it's just at the highest level possible. People
• 9:18
  Speaker 1: is paying attention and listening, so never take the information
• 9:21
  Speaker 1: for granted.
• 9:22
  Speaker 3: Please don't, please don't. It was so dope because he
• 9:25
  Speaker 3: references in video on the new album when he heard
• 9:29
  Speaker 3: that we win, it was just like he was like
• 9:31
  Speaker 3: a sponge like yo word. He's like, I think I
• 9:34
  Speaker 3: met the CEO once, man, like he's a good guy.
• 9:37
  Speaker 1: It was.
• 9:38
  Speaker 3: It was really surreal. Man.
• 9:39
  Speaker 1: Yeah, shout out to nas Man. Somebody said, Nazia Jones.
• 9:42
  Speaker 1: There's only one